Real-World check: Orkambi's safety and effectiveness in 852 CF patients
NCT ID NCT03475381
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study followed 852 people with cystic fibrosis (ages 12 and older) who were taking the drug Orkambi outside of a clinical trial. Researchers wanted to see how many stopped treatment, why, and how their lung function and nutrition changed over one year. The goal was to understand the drug's real-life benefits and risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adult CF center, Service de Pneumologie, Cochin Hospital
Paris, Paris, 75006, France
Conditions
Explore the condition pages connected to this study.